Thymosin β4 compositions

Details Thymosin β4 compositions Thymosin β4 compositions

2007-09-11

2007-09-11

Chism, B. Dell (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S012200, C514S002600, C530S399000, C930S180000

Reexamination Certificate

active

10853505

ABSTRACT:
A composition with a polypeptide including amino acid sequence LKKTET [SEQ ID NO:1] or a conservative variant thereof, the composition further including a carrier for application to a surface of a body.

REFERENCES:
patent: 4389343 (1983-06-01), Horecker
patent: 4543340 (1985-09-01), Goldstein et al.
patent: 5578570 (1996-11-01), Goldstein et al.
patent: 5663071 (1997-09-01), Zetter et al.
patent: 6030948 (2000-02-01), Mann
patent: 6602519 (2003-08-01), Stevenson et al.
patent: 0 124 779 (1984-11-01), None
patent: 0 450 240 (1991-10-01), None
patent: 1 100 529 (2001-05-01), None
patent: WO94/11499 (1994-05-01), None
patent: WO94/18988 (1994-09-01), None
patent: WO94/23739 (1994-10-01), None
patent: WO95/09646 (1995-04-01), None
patent: WO96/16983 (1996-06-01), None
patent: WO97/48805 (1997-12-01), None
patent: WO99/49883 (1999-10-01), None
Malinda et al., FASEB Journal, vol. 11, No. 6, May 1997, pp. 474-481.
Malinda, K.M., et al., “Thymosin B4 stimulates directional migrational of human umbilical vein endothelial cells,” FASEB Journal, vol. 11, No. 6 (1997), pp. 474, 481.
Sun, H-Q, et al., “B-Thymosins are not simple actin monomer buffering proteins. Insights from overexpression studies,” Journal of Biological Chemistry, vol. 271, No. 16 (1996), pp. 9223-9230.
Nimni, M.E., “Polypeptide growth factors: targeted delivery systems,” BIOMATERIALS, vol. 18, No. 18 (1997), pp. 1201-1225.
Frank, S., et al., “Regulation of vascular endothelial growth factor expression in cultured keratinocytes,” Journal of Biological Chemistry, vol. 270, No. 21 (1995), pp. 12607-12613.
Sabolinski, M.L. et al., “Cultured skin as a ‘smart material’ for healing wounds: experience in venous ulcers,” BIOMATERIALS, vol. 17, No. 3, (1996), pp. 311-320.
Hannappel, E., et al., “Actin-sequestering ability of thymosin B4, thymosin B4 fragments, and thymosin B4-like peptides as assessed by theDnase I inhibition assay,” Biol. Chem. vol. 374 (1993), pp. 117-122.
Jorneskog, K., et al., “Low molecular weight heparin seems to improve local capillary circulation and healing of chronic foot ulcers in diabetic patients,”VASA, pp. 137-142, (1993).
Kubler, M. Dominique, et al., “Changes in the distribution of actin-associated proteins during epidermal wound healing”,Journal of Investigative Dermatology, vol. 100, No. 6, (Jun. 1993), pp. 785-789.
Malinda, K.M., et al., “Thymosin β4 accelerates wound healing,”Journal of Investigative Dermatology, vol. 113, No. 6, pp. 364-368, (Sep. 1999).
Cavasin, M.A., et al., “Prolyl oligopeptidase is involved in release of the antifibrotic peptide Ac-SDKP”,Hypertension, May 2004; pp. 1-6; vol. 43.
Peng, H., et al., “Ac-SDKP reverses cardiac fibrosis in rats with renovascular hypertension”,Hypertension, 42; Dec. 2003; pp. 1164-1170.
Philp, D., et al., “Thymosin β4 and a synthetic peptide containing its actin-binding domain promote demal wound repair in db/db diabetic mice and in aged mice”,Wound Rep, and Regen, 11:1; 2003, pp. 19-24.
Philp, D., et al., “Thymosin β4 promotes angiogenesis, wound healing, and hair follicle development”,Mech Ageing Dev., 125:2; 2004; pp. 113-115 (Abstract only).
Philp, D., et al., “The actin binding site of thymosin β4 promotes angiogenesis”,The FASEB Jour., Sep. 18, 2003; 13 pages.
Philp, D., et al., “Thymosin β4 increases hair growth by activation of hair follicle stem cells”,The FASEB Jour., Dec. 4, 2003; 16 pages.
Simenel, C., et al., “Structural requirements for thymosin β4 in its contact with actin: An NMR-analysis of thymosin β4 mutants in solution and correlation with their biological activity”,Eur. J. Biochem., 267; 2000; pp. 3530-3538.
Yang, F, et al., “Ac-SDKP reverses inflammation and fibrosis in rats with heart failure after myocardial infarction”,Hypertension, 43; Feb. 2004; pp. 229-236.
Vancompernolle, K., et al., “G- to F-actin modulation by a single amino acid substitution in the actin binding site of actobindin and thymosin β4”,The EMBO Journal, 11:13; 1992; pp. 4739-4746.
Van Troys, M., et al., “The actin binding site of thymosin β4 mapped by mutational analysis”,The EMBO Journal, 15:2; 1996; pp. 201-210.

Affiliated with

Also associated with

Rating

Thymosin β4 compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Thymosin β4 compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thymosin β4 compositions will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3797456